The overarching theme of Pharma Integrates 2014 is Strategically Transforming Pharma Relationships. Through a series of engaging and interactive panel discussions, participants will share their thoughts and experiences on how to encourage greater collaboration amongst key stakeholders who shape the future of the Pharma industry.
Day 1 : 18th Nov
12:00 : Register and networking refreshments
14:00 – 14:20 : Chairpersons welcome and opening remarks with David Brennan.
14:20 – 15:20 : Strategic Partnering
15:20 – 15:50 : Networking refreshment break
15:50 – 16:50 : Reinventing the Pharmaceutical Business Model
16:50 – 17:50 : Closing the Pharmaceutical Growth Gap
17:50 – 19:30 : Networking champagne reception
14:20 – 15:20 : Strategic Partnering
The Key to Success in the New Healthcare Economy
Healthcare costs (in developed markets at least) are unsustainably high and rapidly increasing as we individuals live longer, get richer and pursue unhealthy lifestyles. Diseases associated with obesity are on the rise. This requires a fundamental rethink into how the players in the healthcare ecosystem collaborate in order to bring patient centred health outcomes to market with demonstrable value payers and providers.
Facilitated by: David Brennan, Event Chair & Former Chief Executive Officer, AstraZeneca
Panellists include: Markus Ewert, Executive Vice President Business Development, GE Healthcare; Martin Kelly, Chief Executive Officer, HealthXL; Martino Picardo, Chief Executive Officer, Stevenage Bioscience Catalyst
Go To Top
15:50 – 16:50 : Reinventing the Pharmaceutical Business Model
Developing the right products with patients
Securing the right patient access to products
Measuring the value of pharmaceutical innovation
Strategic alliances and new collaboration models
Considering disruptive factors, be it new entrants or new technologies
Facilitated by: Trevor Jones CBE, Director Allergan, Chairman Simbec Research & Director VeronaPharma
Panellists include: Cornell Stamoran, Vice President Strategy & Corporate Development, Catalent Pharma Solutions; Tommy Dolan, Vice President Drug Product Design and Supply, Worldwide Research and Development & Pfizer Sandwich Site Head, Pfizer; Andy Jones, Vice President Pharmaceutical Innovation, AstraZeneca; Eliot Forster, Executive Chair, MedCity & Chief Executive Officer, Creabilis
Go To Top
16:50 – 17:50 : Closing the Pharmaceutical Growth Gap – The Supplier Perspective
M&A, Divestments, Pricing and Margin Pressure
Major players, large mergers: big impact on the industry?
Who are the next acquisition targets?
Pricing, margin pressure and unpredictable revenue? How can suppliers respond?
CMO consolidation and one-stop-shop suppliers: is this an on-going trend?
The future of ’boutique’ CMO’s and specialist solution providers
Facilitated by: Jo Pisani, Partner, Pharmaceuticals and Lifesciences Strategy, PricewaterhouseCoopers
Panellists include: Laurent Faboux, Senior Director, Manufacturing Strategy & Third Party Management, Ferring Pharmaceuticals; Andreas Weiler, Global Director Strategic Marketing, SAFC; Douglas Cookson, Vice President Corporate Marketing, Almac Group & Michael Stanek, Managing Director Small Molecule API, Patheon
Go To Top
17:50 – 19:30 : Networking Champagne Reception
View Day 2 Track One Agenda
Day 2 : 19th Nov – Track One
08:30 – 08:55 : Coffee and pastries
9:00 – 10:00 : Outsourcing Overview: Beyond Preferential Pricing
10:05 – 11:05 : Generics: What’s Next?
11:05 – 11:35 : Networking coffee break
11:35 – 12:35 : Biologics vs Biosimilars: The Future of Pharmaceuticals?
12:35 – 13:35 : Networking luncheon
13:35 – 14:35 : Remodelling Pharmaceutical Product Development
14:40 – 15:40 : The Paradigm Shift: From Batch to Continuous
15:40 – 16:00 : Networking coffee break
16:00 – 17:00 : Disruptive Technologies: Preparing for the Future of Pharma
09:00 – 10:00 : Outsourcing Overview: Beyond Preferential Pricing
The New Decision Making Process and Real Drivers
Where’s the real value being generated from strategic partnerships?
On-shoring and off-shoring. Proactive or reactive strategies?
Lessons to be learnt from other sectors (aerospace/automotive/electronics)
Harmonisation, risk sharing and system integration
Facilitated by: Martin Doorbar, Director Product & Device Development, Technical Development, Mundipharma Research
Panellists include: Paula Gildert, Vice President, Global Head Development Strategic Sourcing, Novartis Pharma; Richard Fazackerley, Finished Dose Technical Director, Aesica Pharmaceuticals; Matthew Hanson, Strategic Marketing Lead, SAFC; Mike Mencer, Senior Director Pharmaceutical Development Services, Patheon & Denis Croisat, Director Lead Generation – CMC & Biologics Sourcing & External Business Opportunities, Sanofi
Go To Top
10:05 – 11:05 : Generics: What’s Next?
The next patent cliff: A reality….or just the injectable/biologics players pushing medicines out of reach of ‘most’ generics companies?
Is industry consolidation being driven by the need for ‘specialists’ opposed to ‘generalists’, or the rise of OTC’s and biosimilars?
Growth strategies: Who’s active in actives? Who’s buying brands or developing niche/complex products? Same old, same old or same but different?
Crowded house: Are the big US/EU markets too dominant? Is expansion only an option in emerging markets or with ‘branded’ generics?
Facilitated by: Rahul Garella, Senior Vice President Operations, Par Pharmaceuticals
Panellists include: Kim Kjornas, Executive Director Sales & Marketing RxGx Europe, Actavis; Subir Kohli, Country Head (UK) & Director, Dr Reddy’s Laboratories; Mohit Singh, Associate Vice President Business Development (Europe & North America), Pharmathen and Rory O’Riordan, Executive Director, DCC Vital
Go To Top
11:35 – 12:35 : Biologics vs Biosimilars: The Future of Pharmaceuticals?
Although the first generation of biosimilar products experienced mixed commercial success in Europe, substantial commercial opportunity remains for future biosimilar agents across a wide variety of indications and new biologics continue to carve out niches and evolve current standards of care.
Sales of biologics have continued to grow globally, despite increasing competition from biosimilars. However, developers of new branded biologics are now challenged to demonstrate clinical differentiation and developers of biosimilars are challenged to meet robust clinical comparability requirements.
The discussion will address market trends and opportunities.
Facilitated by: Alan Sheppard, Principal, Global Generics, Thought Leadership, IMS Health
Panellists include: Andrew Sandford, Vice President Global Business Development – Biologics, Catalent Pharma Solutions; Conrad Savoy, Senior Pharma/Biotech Adviser & former Chief Executive Officer, Biopartners & Mateja Urlep, Chief Executive Officer, TikhePharma
Go To Top
13:35 – 14:35 : Remodelling Pharmaceutical Product Development
Putting the Patient First
Differentiating the product profile
Improving production systems and lifecycle management
Incorporating adaptive licensing and patient outcomes
Facilitated by: Daniel Steenstra, Royal Academy of Engineering Visiting Professor of Innovation, Cranfield University
Panellists include: Pall Jonsson, Senior Scientific Adviser, NICE Research & Development, National Institute for Heath and Care Excellence; Professor Luigi Martini, Chair in Pharmaceutical Innovation, King’s College London; Peter Comes, Corporate Vice President End-to-End Supply Network Strategy, Boehringer Ingelheim & Andy Jones, Vice President Pharmaceutical Innovation, AstraZeneca.
Go To Top
14:40 – 15:40 : The Paradigm Shift: From Batch to Continuous
Developing future drugs and dosage forms
Has the traditional pill had its day? Probably not, but increasingly potent APIs, Multiple Unit Pellet Systems, nanoparticles and the rapid implementation of continuous manufacturing, not to mention the rise in parenteral drugs and biopharmaceuticals, is driving the industry to investigate innovative developments in drug production and supply. The routes to future medicines will be discussed and assessed.
Facilitated by: Paul Deutsch, Senior Director & Head, Chemical Process R&D, UCB Pharma
Panellists include: Jon-Paul Sherlock, Director, Product Development UK/US, Pharmaceutical Development, AstraZeneca & Vice President Technical, IChemE; Richard Beesley, IDD/IDDC Business Manager EMEA, 3M Health Care; Mark Buswell, Head of Advanced Manufacturing Technologies, GlaxoSmithKline; Michael O’Brien, Head of Pharmaceutical Sciences Technology & Innovation, Pfizer & Detlef Behrens, Vice President Business Development Finished Dose, Aesica Pharmaceuticals
Go To Top
16:00 – 17:00 : Disruptive Technologies: Preparing for the Future of Pharma
How might disruptive technologies change the pharma industry and the supply base
What are the implications for manufacturing and how do you bring efficiencies
What can Big Pharma learn from other industries?
Overcoming the regulatory challenges of disruptive innovation.
Facilitated by: David Harrison, Manufacturing Alliances Director, Biopharma Operations & Development, UCB Pharma
Panellists include: Clive Badman, Head of Pre-Competitive Collaboration, GlaxoSmithKline; Gunther Busam, Global Program Sourcing Head for Innovations, Novartis Pharma; Keith Williams, Managing Director, Formpipe.GxP; Daniel Steenstra, Royal Academy of Engineering Visiting Professor of Innovation, Cranfield University & Syed Jafri, Global Clinical Director, I&D GBU Healthcare, The Linde Group
Go To Top
View Day 2 Track Two Agenda
Reserve your place today
Day 2 : 19th Nov – Track Two
08:30 – 08:55 : Coffee and pastries
09:00 – 10:00 : Beyond Pills and Potions: The Future of mHealth
10:05 – 11:05 : Emerging Markets: Barriers and Opportunities
11:05 – 11:35 : Networking coffee break
11:35 – 12:35 : Staffing the Future of Pharma
12:35 – 13:35 : Networking luncheon
13:35 – 14:35 : Patients in Charge
14:40 – 15:40 : Harmonising Practices & Protocols for Pharma Industry Efficiency
15:40 – 16:00 : Networking coffee break
16:00 – 17:00 : Disruptive Technologies: Preparing for the Future of Pharma
09:00 – 10:00 : Beyond Pills and Potions: The Future of mHealth
Consumer Technology Drives Real Change in Clinical Research and Healthcare
Patient engagement for clinical trials and beyond
Regulating mobile medical services
Establishing Pharma’s position within the mHealth value chain
Facilitated by: Rowan Gardner, Chief Commercial Officer, RowAnalytics
Panellists include: Wolfgang Renz, President International Business, Physicians Interactive; Alex Black, Marketing Manager, Zambon Group; John Pritchard, Chief Technology Officer Respiratory Drug Delivery Group, Philips Healthcare; Massimo Bresciani, R&D, Director Scientific Operations, Research Centre Pharmaceutical Engineering & Christoph Heinemann, Vice President Strategy & Portfolio Management Diabetes Division, Sanofi
Go To Top
10:05 – 11:05 :Emerging Markets : Barriers and Opportunities
Penetrating Pharmerging Geographies
Pricing, anti-counterfeiting and regulatory compliance
Think local, act local: logistics and supply chain implications
Overcoming saturation, patent expiry and static economies
Africa: from Maghreb to Sub-Sahara, a continent of dynamic market potential for sustainable pharmaceutical business models
Facilitated by: Jo Pisani, Partner, Pharmaceuticals and Lifesciences Strategy, PricewaterhouseCoopers
Panellists include: Harriet Fear, Chief Executive Officer, One Nucleus; Jonathan Blamey, Vice President, Global Product & Account Leader, Global Life Sciences & Healthcare, DHL Supply Chain & Sarah Rickwood, Director European Thought Leadership, IMS Health
Go To Top
11:35 – 12:35 : Staffing the Future of Pharma
Finding, Getting and Keeping the Right People
Talent acquisition and cultural organisation
New skillsets and expertise for improved succession planning
Beyond HR: changing the corporate mindset
Think future, think personnel
Facilitated by: Professor Luigi Martini, Chair in Pharmaceutical Innovation, King’s College London
Panellists include: Paul Stuart, Vice President Pharmaceutical Sciences Supply Chain, Pfizer; Sarah Haywood, Head of Life Sciences, London & Partners and Chief Operating Officer, MedCity; Nick Stephens, Executive Chairman, RSA
Go To Top
13:35 – 14:35 : Patients in Charge
From patient advocacy to personalised medicine, a multifaceted approach is needed to expedite early stage drug development and innovate the future of Big Pharma
The increasing role and value of patient advocacy
Extending the value chain to ensure that products meet patient needs
Patient-tailored medication (paediatric, geriatric and orphan drugs)
Accelerating personalised medicine with companion diagnostics
Facilitated by: Tina Flatau, Managing Director, Biopharma Projects
Panellists include: Josie Godfrey, Associate Director Highly Specialised Technologies, National Institute for Health and Care Excellence (NICE); Nicolas Sireau, Chairman and Chief Executive Officer, AKU Society & Chairman, Findacure; Austin Tanney, Marketing Manager Diagnostic and Discovery Business Units, Almac Group & Didier Caizergues, Director of Regulatory Affairs, Genethon
Go To Top
14:40 – 15:40 : Harmonising Practices & Protocols for Pharma Industry Efficiency
Establishing a governance framework and effective management systems
Implementing internal audits for continuous improvement and risk control
Integrating, engaging, understanding and optimising best practices
Greater standardisation in areas such as EH&S and distribution will also be addressed.
Facilitated by: Hitesh Varambhia, Head of External Manufacturing APAC, Corporate QA Commercial Pharma, UCB Pharma
Panellists include: Sue Coote, Head Non-Clinical Global Outsourcing Management, GlaxoSmithKline, GSK Medicines Research Centre; Richard Holland, Executive Director Operations, Pistoia Alliance; Mike Meakin, Vice President Global Quality Regulatory and Compliance, Life Sciences & Healthcare, DHL Supply Chain & Axel Sinner, Principal, Camelot Management Consultants
Go To Top
16:00 – 17:00 : Disruptive Technologies: Preparing for the Future of Pharma
How might disruptive technologies change the pharma industry and the supply base
What are the implications for manufacturing and how do you bring efficiencies
What can Big Pharma learn from other industries?
Overcoming the regulatory challenges of disruptive innovation.
Facilitated by: David Harrison, Manufacturing Alliances Director, Biopharma Operations & Development, UCB Pharma
Panellists include: Clive Badman, Head of Pre-Competitive Collaboration, GlaxoSmithKline; Gunther Busam, Global Program Sourcing Head for Innovations, Novartis Pharma; Keith Williams, Chief Executive Officer, GXPi; Daniel Steenstra, Royal Academy of Engineering Visiting Professor of Innovation, Cranfield University & Syed Jafri, Global Clinical Director, I&D GBU Healthcare, The Linde Group